A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed or refractory multiple myeloma, according to results of a single-center, single-arm phase 2 clinical trial published in The Lancet Haematology. The dual CAR T-cell combination resulted in a 95% response rate, with 43% of patients achieving...Continue Reading